research Severe form of keratitis–ichthyosis–deafness (KID) syndrome associated with septic complications
Infants with severe KID syndrome may be more prone to serious infections and need close monitoring.
Search
for
Sort by
Research
240-270 / 1000+ results
research Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
research 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
research Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
research A novel mutation in the connexin 26 gene (GJB2) in a child with clinical and histological features of keratitis–ichthyosis–deafness (KID) syndrome
A new gene mutation linked to KID syndrome was found, expanding genetic knowledge.
research Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
research Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
Baricitinib is an effective treatment for severe alopecia areata.
research Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research Baricitinib: A Review in Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
research Worldwide Clinical and Real-World Exposure to Baricitinib
Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
research Zizyphus jujubaprotects against ibuprofen-induced nephrotoxicity in rats
Jujube fruit extract may reduce kidney damage from ibuprofen in rats.
research Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
research Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Oral JAK inhibitors help regrow hair in alopecia areata with manageable side effects.
research In‐silico Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its In‐vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
research Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
research JAK inhibition decreases the autoimmune burden in Down syndrome
JAK inhibition reduces autoimmune issues in Down syndrome.
research Baricitinib Induced Hypoglycemic Seizures in a Patient with Hair Loss and Type I Diabetes Mellitus: A Case Report
Baricitinib may cause low blood sugar in some patients, so careful monitoring is needed.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Ruxolitinib found to cause eyelash growth: a case report
Ruxolitinib treatment may cause eyelash growth.
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research Localized variant of junctional epidermolysis bullosa with R795X mutation
Early and accurate diagnosis is crucial for managing rare genetic disorders like this localized variant of junctional epidermolysis bullosa.
research Janus kinase (JAK)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.